S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
C Mayer,
D Cooper,
A Redfern,
X Geng,
J Shi,
M Zutphen-van Geffen,
I Kuan,
K Koek,
H Kastrissios,
K Patel,
M Davis,
P Yue
Affiliations
C Mayer
1 Semivida Research, Dallas, UNITED STATES
D Cooper
2 Daniel S Cooper, MD, LLC, Palo Alto, UNITED STATES
A Redfern
3 Linear Clinical Research, Nedlands, AUSTRALIA
X Geng
4 Global Blood Therapeutics, South San Francisco, UNITED STATES
J Shi
4 Global Blood Therapeutics, South San Francisco, UNITED STATES
M Zutphen-van Geffen
5 Certara USA, Inc., Princeton, UNITED STATES
I Kuan
5 Certara USA, Inc., Princeton, UNITED STATES
K Koek
5 Certara USA, Inc., Princeton, UNITED STATES
H Kastrissios
5 Certara USA, Inc., Princeton, UNITED STATES
K Patel
5 Certara USA, Inc., Princeton, UNITED STATES
M Davis
4 Global Blood Therapeutics, South San Francisco, UNITED STATES
P Yue
4 Global Blood Therapeutics, South San Francisco, UNITED STATES
